Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD) requires lifelong immunosuppression to prevent relapses and disability. However, long-term treatment can increase the risk of severe and opportunistic infections, which can lead to hospitalisation and death. OBJECTIVES: To describe severe infections in AQP4-IgG NMOSD, their outcomes and risk factors, to inform safer long-term management. METHODS: We retrospectively analysed prospectively collected data from 209 patients with AQP4-IgG NMOSD treated with immunosuppressive therapies and followed ⩾1 year at a UK national specialist service. Severe infections were defined as requiring intravenous therapy or hospitalisation. Predictors were identified using multivariate regression. RESULTS: Forty-nine severe/opportunistic infections occurred in 37 patients (18%), accounting for one-third of deaths (10/30). Independent predictors were longer disease duration (OR 1.10, 95% CI 1.01-1.21), older age at onset (OR 1.04, 95% CI 1.00-1.08), comorbid autoimmune disease (OR 3.91, 95% CI 1.95-7.84) and diabetes mellitus (OR 7.48, 95% CI 2.24-24.98). Four patients died after their first infection. Among survivors, nine developed recurrent infections, six of whom died. CONCLUSIONS: Severe infections can be a complication of immunosuppression in NMOSD, especially in older patients and those with comorbidities. Risk stratification, comorbidity management and infection prevention should guide therapy to balance safety and relapse control.

More information Original publication

DOI

10.1177/13524585251409581

Type

Journal article

Publication Date

2026-01-31T00:00:00+00:00

Keywords

NMOSD, aquaporin-4 antibodies, comorbidities, immunosuppression, infection risk